Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SEP-363856 is an agent of orally active and CNS active psychotropic with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects, has the potential to treatment of schizophrenia.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | SEP-363856 is an agent of orally active and CNS active psychotropic with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects, has the potential to treatment of schizophrenia. |
Targets&IC50 | 5-HT2C receptor:30 μM (EC50), 5-HT1D receptor:0.262 μM (EC50), 5-HT1A receptor:2.3 μM (EC50), 5-HT7 receptor:6.7 μM (EC50), 5-HT1B receptor:15.6 μM (EC50), 5-HT2A receptor:10 μM (EC50), TAAR1:0.140 μM (EC50) |
In vitro | SEP-856 (10μM) specifically inhibits α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C and 5-HT7> 50% receptor. |
In vivo | SEP-856 (0.3, 1 and 10 mg/kg, i.p.) is CNS active. SEP-856 exhibits a behavioral signature similar to known antipsychotic drugs.PCP-induced hyperactivitysignificantly reduced by SEP-856 (0.3, 1 and 10 mg/kg, orally once) . Oral SEP-856 administration (1, 3 and 10 mg/kg) produces a dosedependent decrease in REM sleep, increase in latency to REM sleep and increase in cumulative wake (W) time. |
Synonyms | SEP-856 |
Molecular Weight | 183.27 |
Formula | C9H13NOS |
CAS No. | 1310426-33-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SEP-363856 1310426-33-5 Others SEP 856 SEP 363856 SEP363856 SEP856 SEP-856 inhibitor inhibit